FDA to Host Advisory Committee Meeting on Donanemab’s TRAILBLAZER-ALZ 2 Study
Eli Lilly and Company (NYSE: LLY) has announced that the U.S. Food and Drug Administration (FDA) plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory…
Mirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading biopharmaceutical firm specializing in the discovery, acquisition, development, and distribution of innovative therapies for rare and orphan diseases, has revealed its participation in…
Oragenics, Inc. Readies Phase II Clinical Trials for Concussion Treatment Drug
Oragenics, Inc. (NYSE American: OGEN), a company dedicated to developing innovative intranasal pharmaceuticals for neurological disorders, has revealed its readiness to embark on the final stages of GMP manufacturing and…
Gossamer Bio’s 2023 Financial Report and Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on seralutinib for pulmonary arterial hypertension (PAH) treatment, reported its financials for Q4 and full-year 2023 and updated on business…
Alnylam’s KARDIA-2 Study Shows Zilebesiran Adds Significant Blood Pressure Reduction
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNAi therapeutics, has announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT)…
Argonaut Manufacturing Services Boosts Aseptic Pharma Filling with $45M Investment
Argonaut Manufacturing Services Secures $45M Funding for Expanded Pharma Fill / Finish Facility Argonaut Manufacturing Services, a prominent contract development and manufacturing organization in the biopharma and life sciences sectors,…
Aktana Unveils Advanced Omnichannel Tools for Med-Tech Firms
Aktana Unveils “Aktana for MedTech” to Revolutionize HCP Engagement Aktana, the forefront in intelligent customer engagement for global life sciences and the medical sector, has introduced “Aktana for MedTech.” This…
Summit Therapeutics at Barclays 26th Global Healthcare Conference
Summit Therapeutics (NASDAQ: SMMT) will present at the Barclays 26th Global Healthcare Conference in Miami Beach, FL from March 12-14, 2024. CEO Dr. Maky Zanganeh and Chairman Robert W. Duggan…
2032 Myocardial Infarction Treatment Insights: FARXIGA Forecast – ResearchAndMarkets.com
ResearchAndMarkets.com is pleased to announce the addition of the “FARXIGA Market Size, Forecast, and Emerging Insight – 2032” report to its offerings. This comprehensive report delves into the impact and…
Merck’s Involvement Confirmed for the Barclays 26th Annual Global Healthcare Conference
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has revealed that Jannie Oosthuizen, President of Human Health U.S., is set to engage in a fireside…
Expanded Collaboration for Neoantigen Cancer Vaccine Trial
Transgene (Euronext Paris: TNG), a biotechnology company specializing in virus-based immunotherapies for cancer treatment, NEC Corporation (NEC; TSE: 6701), a leader in IT, network, and AI technologies, and BostonGene Corporation…
United Therapeutics Corporation Scheduled to Participate in the Leerink Partners Global Biopharma Conference 2024
United Therapeutics Corporation (Nasdaq: UTHR), a leading public benefit corporation, has disclosed that Patrick Poisson, Executive Vice President of Technical Operations, will participate in a fireside chat session at the…